Biogen Teams with Ginkgo Bioworks on Gene Therapy

Mass.-based drugmakers Biogen and Ginko Bioworks have partnered to produce new gene therapies using adeno-associated virus (AAV)-based vectors.

Gingko will leverage its mammalian cell programming platform to make more AAV-producing plasmid vectors and cell lines to help Biogen manufacture more gene therapies at scale.

Under the deal, Biogen will pay Ginkgo $5 million upfront with Gingko eligible to receive up to $115 million in milestone-based payments.